Comparison of Prophylactic Acyclovir and Placebo in Prevention of Eczema Herpeticum in Pediatric Burns

NACompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

October 1, 2019

Primary Completion Date

September 30, 2020

Study Completion Date

September 30, 2020

Conditions
Herpes Virus Infection
Interventions
DRUG

Intravenous Acyclovir

Patients were observed for developing signs of eczema herpeticum and Tzanck smear was done every 10th day and first follow up at OPD after 7days of discharge following ward management protocol. If prophylactic acyclovir was efficacious then no eczema herpeticum developed. Patients who develop eczema herpeticum were isolated and were treated with injection acyclovir 15 to 30 mg/kg/day into three divided doses for 10 to 14 days.

Trial Locations (1)

54000

department of pediatric surgery King Edward Medical University, Lahore

All Listed Sponsors
lead

King Edward Medical University

OTHER

NCT06380647 - Comparison of Prophylactic Acyclovir and Placebo in Prevention of Eczema Herpeticum in Pediatric Burns | Biotech Hunter | Biotech Hunter